Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback